NeRRe Therapeutics raises £20 million in a Series B2 financing round NeRRe Therapeutics raises £20 million in a Series B2 financing round New funds to evaluate orvepitant as a treatment for the disabling chronic cough associated with idiopathic pulmonary fibrosis...

NeRRe Therapeutics raises £20 million in a Series B2 financing round NeRRe Therapeutics raises £20 million in a Series B2 financing round New funds to evaluate orvepitant as a treatment for the disabling chronic cough associated with idiopathic pulmonary fibrosis...

NeRRe Therapeutics announces positive findings from Phase 2b study with orvepitant in chronic cough NeRRe Therapeutics announces positive findings from Phase 2b study with orvepitant in chronic cough ~ Statistically significant and clinically relevant improvements in patient reported outcomes in...

NeRRe Therapeutics announces positive findings from Phase 2b study with orvepitant in chronic cough NeRRe Therapeutics announces positive findings from Phase 2b study with orvepitant in chronic cough ~ Statistically significant and clinically relevant improvements in patient reported outcomes in...